Complete response to azacitidine priming and nab‑paclitaxel in non‑Hodgkin lymphoma resistant to biochemotherapy

Bowen,Randy C.; Hahn,Andrew W.; Butler,Thomas W.; Khong,Hung T.

doi:10.3892/mco.2016.1090

Complete response to azacitidine priming and nab‑paclitaxel in non‑Hodgkin lymphoma resistant to biochemotherapy

Authors:
- Randy C. Bowen
- Andrew W. Hahn
- Thomas W. Butler
- Hung T. Khong
View Affiliations

Affiliations: Department of Internal Medicine, University of Utah Salt Lake, UT 84112, USA, Department of Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA, Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake, UT 84112, USA
Published online on: November 23, 2016 https://doi.org/10.3892/mco.2016.1090
Pages: 122-124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The standard of care for first‑line therapy in diffuse large B-cell lymphoma (DLBCL) is the rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‑CHOP) regimen. For patients who fail to respond, have an incomplete response or relapse, numerous effective options exists besides salvage cisplatin‑based regimen and autologous stem cell therapy. Even with this approach, the outcome remains very poor for this group of patients. The present case illustrates a 55‑year‑old woman diagnosed with DLBCL, who experienced an early incomplete response, later progression during treatment with the R‑CHOP regimen. The patient received salvage therapy with rituximab, cisplatin and gemcitabine, again with an incomplete response. The patient declined consideration for stem cell therapy. Her disease progressed and she enrolled in the present phase I trial using azacitadine priming and nanoalbumin‑bound (nab)‑paclitaxel. After three cycles, follow‑up positron emission tomography/computed tomography revealed a complete response for the first time since her initial diagnosis and the patient has remained disease‑free for >6 years. Azacitadine and nab‑paclitaxel combination appeared to be an effective regimen for the treatment of this patient with refractory DLBCL.

View Figures

View References

1	Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA and Edwards BK: Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 103:714–736. 2011. View Article : Google Scholar : PubMed/NCBI
2	Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD and Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 107:265–276. 2006. View Article : Google Scholar : PubMed/NCBI
3	Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011:498–505. 2011.PubMed/NCBI
4	Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, et al: Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 103:3684–3688. 2004. View Article : Google Scholar : PubMed/NCBI
5	Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, et al: Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 24:593–600. 2006. View Article : Google Scholar : PubMed/NCBI
6	Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, Imrie K, Myers R, Adams G, Ding K, et al: Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: A Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 101:1835–1842. 2004. View Article : Google Scholar : PubMed/NCBI
7	Velasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Romaguera J, Rubenstein E and Cabanillas F: ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol. 12:1169–1176. 1994.PubMed/NCBI
8	López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J and Rodríguez J: GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: A phase II study. Eur J Haematol. 80:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
9	Thieblemont C and Coiffier B: Lymphoma in older patients. J Clin Oncol. 25:1916–1923. 2007. View Article : Google Scholar : PubMed/NCBI
10	Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP and Fisher RI: Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246. J Clin Oncol. 16:574–578. 1998.PubMed/NCBI
11	Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel P, Quesnel B, et al: Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica. 85:502–507. 2000.PubMed/NCBI
12	Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J and Jumonville A: Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: A Wisconsin Oncology Network Study. Cancer Invest. 23:13–18. 2005. View Article : Google Scholar : PubMed/NCBI
13	Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, et al: Paclitaxel, topotecan and rituximab: Long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 167:177–184. 2014. View Article : Google Scholar : PubMed/NCBI
14	Wu L, Wang J, Li Y, Zuo L, Zhang Z, Ouyang J, Fan J and Li H: Development of taxane-containing chemotherapy of doxorubicin-resistant diffuse large B-cell lymphoma. Anticancer Drugs. 25:826–831. 2014. View Article : Google Scholar : PubMed/NCBI
15	Minshall RD, Tiruppathi C, Vogel SM and Malik AB: Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function. Histochem Cell Biol. 117:105–112. 2002. View Article : Google Scholar : PubMed/NCBI
16	Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 12:1317–1324. 2006. View Article : Google Scholar : PubMed/NCBI
17	Gupta N, Hatoum H and Dy GK: First line treatment of advanced non-small-cell lung cancer-specific focus on albumin bound paclitaxel. Int J Nanomedicine. 9:209–221. 2014.PubMed/NCBI
18	Sage H, Johnson C and Bornstein P: Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem. 259:3993–4007. 1984.PubMed/NCBI
19	Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest. 115:1492–1502. 2005. View Article : Google Scholar : PubMed/NCBI
20	Sato N, Fukushima N, Maehara N, Matsubayashi H, Koopmann J, Su GH, Hruban RH and Goggins M: SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene. 22:5021–5030. 2003. View Article : Google Scholar : PubMed/NCBI
21	Suzuki M, Hao C, Takahashi T, Shigematsu H, Shivapurkar N, Sathyanarayana UG, Iizasa T, Fujisawa T, Hiroshima K and Gazdar AF: Aberrant methylation of SPARC in human lung cancers. Br J Cancer. 92:942–948. 2005. View Article : Google Scholar : PubMed/NCBI
22	Mok SC, Chan WY, Wong KK, Muto MG and Berkowitz RS: SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene. 12:1895–1901. 1996.PubMed/NCBI
23	Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW, et al: Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov. 3:1002–1019. 2013. View Article : Google Scholar : PubMed/NCBI
24	Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI